We’ve signed a definitive agreement to acquire Lantheus’ SPECT division, a leader in nuclear diagnostics. This means broader access to life-saving diagnostics, faster launches of more isotopes from Chrysalis, and a world-class team joining us. PR here:

Most kids played at recess. Greg Piefer read about fusion. That early spark led to a mission: use fusion to solve problems & improve lives. He recently received UW–Madison’s 2025 Chancellor’s Entrepreneurial Achievement Award. 📸Focal Flame Photography

We've partnered with Modawina Medical Company to bring Ilumira (n.c.a. Lu-177) to the UAE. This expands our global footprint in medical isotopes and ensures more patients can access these cancer therapies. We're taking another step forward in making precision medicine global!

We're proud to put Janesville, Wisconsin on the map for nuclear fusion! .Great article spotlighting numerous Wisconsin fusion companies and partners Realta, TypeOne and Wisconsin Alumni Research Foundation (WARF).

Congrats to our founder and CEO, Greg Piefer for being named one of Wisconsin's Most Influential Business Leaders. . #Wisconsin275

Our Business Development Manager of Isotopes, David Bailey will discuss “A Supply Chain Lens: Exploring Isotope Viability from Production Challenges to Market Potential” on a panel, this week Thursday at TRP EU. Tune in on the conversation if you are attending the conference.

"We aim to end these shortages," says our founder and CEO @GregPiefer in this @WIRED article examining the global medical isotope crisis and its impact on patient care. Read more:

Curious how modern cancer treatments target tumors while sparing healthy tissue? We explain the science behind non-carrier-added lutetium-177 (n.c.a. Lu-177) and why domestic production is key to making this life-saving therapy more accessible than ever.

We're seeing exciting progress at Chrysalis, soon to be the world's largest medical isotope production and irradiation facility. Every milestone brings us closer to producing millions of doses of life-saving cancer medicines right here in Wisconsin.

Another great week of producing and shipping Ilumira (n.c.a. Lu-177) to support critical cancer research and treatments! When patients need treatment, every day matters.

Take a look inside Chrysalis, our state-of-the-art production facility under construction in Janesville, WI. As our founder and CEO @GregPiefer explains, it will be "the first major beneficial use of fusion to benefit humanity on a massive scale."

When it comes to supporting the world’s need for nuclear medicine, one product shines bright. Ilumira, our n.c.a. Lu-177, offers unmatched radionuclidic purity and immediate worldwide shipping to bring life-saving medicine within reach.

As we observe #NuclearSciWeek, we're looking ahead to clean energy's future. Our ultimate goal: harnessing fusion for power generation. We're building expertise and infrastructure step by step.

We're working to recycle used fuel, making nuclear energy more sustainable. As support grows, we're committed to developing clean, safe energy solutions for the future. #CleanEnergy

Medical isotopes such as lutetium-177 can save lives. But supply shortages are a critical challenge in healthcare. Our approach creates a cleaner, safer, more reliable supply of critical diagnostic and therapeutic isotopes.

This #NuclearSciWeek, we're showcasing how fusion tech enhances industrial safety. We use neutron imaging for advanced, nondestructive testing in aerospace, defense, and energy.

Lu-177 illuminates hope for patients with cancer with the ability to precisely target tumors and metastases with potent radiation, destroying cancer cells while minimizing harm to healthy tissue. Learn more here:

Good morning, #EANM2024!. Come stop by our booth for a fresh cup of coffee from our barista. Booth S47 is here to talk to you about our n.c.a. Lutetium-177. See you here!

Get your mid-conference caffeine buzz at #EANM2024! Join us at booth #S47 for gourmet coffee and chats about our Lu-177 production & collabs. See you tomorrow!